Jerome Benedict Durso
Insider (Form 4 reporting owner): President and CEO CIK 1698665Name as filed: Durso Jerome BenedictIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 22 Dec 2025, bought $263K in 5 open-market purchases of Altimmune.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Altimmune ALT | President and CEO | 22 Dec 2025 | 13 Nov 2026 | 5$263K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades4 trades | too few trades3 trades | no trade old enough |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | 4 | $212K | – | – | $212K |
| 2025 | 1 | $52K | – | – | $52K |
Every trade
5, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 13 Nov 2026 | Altimmune ALT | Buy | 30,700 | $1.62 | $50K | No | Form 4filed 13 Nov 2026 |
| 13 Aug 2026 | Altimmune ALT | Buy | 15,000 | $2.95 | $44K | No | Form 4filed 13 Aug 2026 |
| 1 Apr 2026 | Altimmune ALT | Buy | 15,000 | $3.14 | $47K | No | Form 4filed 1 Apr 2026 |
| 6 Mar 2026 | Altimmune ALT | Buy | 20,000 | $3.54 | $71K | No | Form 4filed 9 Mar 2026 |
| 22 Dec 2025 | Altimmune ALT | Buy | 12,500 | $4.13 | $52K | No | Form 4filed 22 Dec 2025 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.